Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Victoria Kletas"'
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:198-204
Since the introduction of regulatory drug approval guidance on the evaluation of QT interval prolongation, an increasing number of drug monographs has included cautions on the risk of QT prolongation. For example, QT prolongation is mentioned in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c602cac794166695e8c290c11e07584b
https://doi.org/10.1177/1078155217748735
https://doi.org/10.1177/1078155217748735
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(1)
Background Standard dosing regimen of sunitinib for metastatic renal cell carcinoma consists of four weeks treatment followed by two weeks rest (intermittent dosing). Alternative regimens have been suggested, including continuous daily dosing (contin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792dbcb92b6848206ba4aa300c6c9b31
https://pubmed.ncbi.nlm.nih.gov/30909792
https://pubmed.ncbi.nlm.nih.gov/30909792
Autor:
Victoria Kletas, Mário L de Lemos
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:18-21
Background New oncology drugs usually become commercially available several months before the funding decisions are made by provincial public payers. Increasingly, patient assistance programs are being set up by pharmaceutical companies in order to f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bca21d9a486c037312d7637cb5592e3
https://doi.org/10.1177/1078155216677854
https://doi.org/10.1177/1078155216677854
Publikováno v:
Journal of Oncology Pharmacy Practice. 24:634-636
High-dose loperamide is often used for the acute management of chemotherapy-induced diarrhea, with a maximum daily dosing of up to 24 mg. Recently, the US Food and Drug Administration has issued a warning that loperamide can cause rare serious cardia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f208440baedf2303929907e453e5524
https://doi.org/10.1177/1078155217718384
https://doi.org/10.1177/1078155217718384
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 24(3)
It has been argued that the larger molecular weight of hazardous monoclonal antibodies may prevent their dermal absorption via occupational exposure. However, this assertion does not seem to be supported by direct evidence. Although the larger molecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f03aedf86a258728624e7930fc4f96
https://pubmed.ncbi.nlm.nih.gov/29284346
https://pubmed.ncbi.nlm.nih.gov/29284346
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 18(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca67d2cb91f11e84a32eb66006f53fa
https://pubmed.ncbi.nlm.nih.gov/22573212
https://pubmed.ncbi.nlm.nih.gov/22573212
Publikováno v:
Journal of Clinical Oncology. 32:417-417
417 Background: Standard dosing regimen of sunitinib for metastatic renal cell carcinoma (mRCC) consists of 4 weeks treatment followed by 2-weeks rest (intermittent dosing, ID). Alternative regimens have been suggested, including continuous daily dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95336645c15d54219e5c03d4caec9cd6
https://doi.org/10.1200/jco.2014.32.4_suppl.417
https://doi.org/10.1200/jco.2014.32.4_suppl.417
Publikováno v:
Journal of Clinical Oncology. 31:e15541-e15541
e15541 Background: Standard dosing regimen of sunitinib for metastatic renal cell carcinoma (mRCC) consists of 4 weeks treatment followed by 2 weeks rest (intermittent dosing, ID). Alternative regimens have been suggested, including daily dosing regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c341111b982dead688e92f7bae67a2a7
https://doi.org/10.1200/jco.2013.31.15_suppl.e15541
https://doi.org/10.1200/jco.2013.31.15_suppl.e15541